Remimazolam and Propofol on the Left Ventricular Strain During Anesthesia Induction for Non-cardiac Surgery

Launched by KONKUK UNIVERSITY MEDICAL CENTER · Jun 7, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different medications, remimazolam and propofol, to see how they affect the heart during anesthesia induction for non-cardiac surgeries. The main focus is on a specific measurement called left ventricular global longitudinal strain (LV-GLS), which helps doctors understand how well the heart is functioning while a patient is put under anesthesia. To measure LV-GLS, a safe and non-invasive technique called echocardiography will be used.

To participate in this trial, you need to be at least 18 years old and have a certain level of heart function, meaning your heart should be pumping well (with an ejection fraction greater than 50%) and not have any specific local problems with movement. However, people with certain conditions like atrial fibrillation (an irregular heartbeat) or those who may have difficulty breathing during the procedure won't be eligible. If you participate, you can expect to receive either remimazolam or propofol before your surgery, and the study will closely monitor your heart's response during this time. This research aims to improve understanding of how these medications impact heart health during surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • left ventricular ejection fraction\> 50%
• • no left ventricular regional wall motion abnormality
• Exclusion Criteria:
• • atrial fibrillation
• • unfavorable airway
• • hypotension requiring inotropic support